188 related articles for article (PubMed ID: 30496989)
1. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Li P; Basnet SK; Kumarasiri M; Diab S; Teo T; Albrecht H; Wang S
Eur J Med Chem; 2015 May; 95():116-26. PubMed ID: 25800647
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
[TBL] [Abstract][Full Text] [Related]
4. Sulfoximine substituted quinazolines for pharmaceutical compositions US 20150005278 (A1): a patent evaluation.
Gopaul K; Koorbanally NA
Expert Opin Ther Pat; 2016 Aug; 26(8):861-9. PubMed ID: 27146589
[TBL] [Abstract][Full Text] [Related]
5. Progress in developing MNK inhibitors.
Jin X; Yu R; Wang X; Proud CG; Jiang T
Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
[TBL] [Abstract][Full Text] [Related]
6. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
7. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.
Xie J; Shen K; Jones AT; Yang J; Tee AR; Shen MH; Yu M; Irani S; Wong D; Merrett JE; Lenchine RV; De Poi S; Jensen KB; Trim PJ; Snel MF; Kamei M; Martin SK; Fitter S; Tian S; Wang X; Butler LM; Zannettino ACW; Proud CG
Cell Mol Life Sci; 2021 Jan; 78(1):249-270. PubMed ID: 32170339
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and Evaluation of Novel Phorbazole C Derivatives as MNK Inhibitors through Virtual High-Throughput Screening.
Jin X; Li M; Qiu T; Yu R; Jiang T
Mar Drugs; 2022 Jun; 20(7):. PubMed ID: 35877722
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
14. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
[TBL] [Abstract][Full Text] [Related]
15. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
[TBL] [Abstract][Full Text] [Related]
16. Mnk inhibitors: a patent review.
Abdelaziz AM; Yu M; Wang S
Pharm Pat Anal; 2021 Jan; 10(1):25-35. PubMed ID: 33441033
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
[TBL] [Abstract][Full Text] [Related]
18. The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding.
Beggs JE; Tian S; Jones GG; Xie J; Iadevaia V; Jenei V; Thomas G; Proud CG
Biochem J; 2015 Apr; 467(1):63-76. PubMed ID: 25588502
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]